Last updated: September 16, 2026
Meglumine is a mature, multifunctional pharmaceutical excipient used primarily as a solubilizer, pH modifier, counterion and formulation aid. Its commercial demand is tied less to standalone excipient consumption than to injectable contrast media, radiopharmaceuticals, generic injectable medicines and selected poorly soluble active ingredients. The market is fragmented, with limited public disclosure of meglumine-specific sales, pricing or margins.
The financial outlook is stable rather than high-growth. Volume demand should remain supported by pharmaceutical manufacturing and diagnostic imaging, while pricing power is constrained by multiple qualified suppliers, a relatively simple chemical structure and the availability of alternative salts or formulation systems.
What is meglumine and how is it used in pharmaceutical products?
Meglumine, also called N-methyl-D-glucamine, is an amino sugar derived from glucose. It has the molecular formula C7H17NO5, a molecular weight of approximately 195.21 g/mol and CAS Registry Number 6284-40-8. PubChem classifies it as an amino alcohol and carbohydrate derivative (National Center for Biotechnology Information, 2024).
Its principal pharmaceutical functions are:
| Function |
Commercial role |
| Counterion |
Forms salts with acidic active pharmaceutical ingredients |
| Solubilizer |
Improves aqueous solubility of poorly soluble compounds |
| pH modifier |
Adjusts formulation pH, particularly in parenteral products |
| Buffer component |
Helps control formulation stability |
| Excipient |
Supports injectable, oral and topical dosage forms |
| Process aid |
Assists API isolation or conversion into a usable salt |
Meglumine is best known in contrast media, including salts such as gadopentetate dimeglumine, gadobenate dimeglumine, gadodiamide and diatrizoate meglumine. It also appears in certain injectable and oral pharmaceutical products where increased water solubility is required.
What pharmaceutical products contain meglumine?
Contrast media and diagnostic imaging products
The largest demand center is diagnostic imaging. Meglumine has historically been used to create water-soluble salts of iodinated and gadolinium-based contrast agents.
Representative products include:
| Product or active ingredient |
Meglumine-related use |
| Gadopentetate dimeglumine |
Gadolinium MRI contrast agent |
| Gadobenate dimeglumine |
Gadolinium MRI contrast agent |
| Gadodiamide |
Gadolinium MRI contrast agent |
| Diatrizoate meglumine |
Iodinated X-ray and CT contrast agent |
| Iothalamate meglumine |
Iodinated contrast agent |
| Ioxaglate meglumine |
Ionic iodinated contrast agent |
The commercial importance of individual products varies by geography. Some older gadolinium agents have lost share to newer macrocyclic products, while iodinated contrast media remain essential in CT, angiography and interventional procedures.
The FDA’s Inactive Ingredient Database records meglumine in approved drug products and provides evidence of regulatory precedent for its use by route and dosage form (U.S. Food and Drug Administration, 2024a). The database does not confer independent approval on meglumine as a general-purpose excipient.
Non-contrast pharmaceutical formulations
Outside imaging, meglumine may be used in:
- Injectable salts of acidic APIs
- Oral solutions and suspensions
- Topical and dermatological products
- Veterinary pharmaceutical formulations
- Research compounds and development-stage formulations
- Long-acting or depot systems requiring enhanced API solubility
Commercial adoption depends on formulation-specific performance. A manufacturer must establish compatibility, impurity control, microbial quality, residual solvents, elemental impurities and stability under the intended manufacturing process.
How large is the meglumine pharmaceutical excipient market?
No major public company separately reports meglumine revenue. Market research providers generally group it into broader categories such as pharmaceutical excipients, solubilizers, amino-sugar derivatives or contrast-media ingredients. As a result, standalone market-size estimates are less reliable than downstream demand indicators.
The market has four structural characteristics:
- Contrast media create the most visible demand pool.
- Generic injectables support recurring but price-sensitive volume.
- Supplier qualification limits rapid switching once a product is registered.
- The chemical is mature, keeping margins below those of specialized excipients or novel delivery technologies.
Meglumine demand is therefore best modeled as a derived market. A practical demand equation is:
Meglumine demand = contrast-media production + injectable drug production + oral and topical formulation use + development and laboratory demand
The first component is the most commercially significant. Imaging volumes are affected by population aging, cancer diagnosis, cardiovascular disease, hospital capacity and reimbursement. Demand can also be disrupted by contrast-media manufacturing outages, as demonstrated by supply constraints affecting iodinated contrast products in recent years.
What is the financial trajectory for meglumine suppliers?
The financial trajectory is likely to be characterized by stable volume, modest price growth and periodic margin volatility.
Revenue drivers
Supplier revenue is influenced by:
- Production volumes for gadolinium and iodinated contrast media
- Growth in generic injectable manufacturing
- New formulation approvals using meglumine salts
- Regional pharmaceutical capacity expansion
- Regulatory requalification of manufacturing sites
- Demand for higher-purity parenteral grades
Margin drivers
Margins are affected by:
- Glucose and amine feedstock costs
- Energy and water consumption
- Purification requirements
- Batch size and plant utilization
- Quality-system overhead
- Freight and hazardous-goods logistics
- Customer audits and regulatory inspections
- The number of approved alternative suppliers
Standard industrial or technical-grade meglumine has limited pricing power. Pharmaceutical-grade material can command a premium because customers require validated manufacturing, controlled impurity profiles, traceability and documentation. The premium is greater for injectable use than for laboratory or nonsterile applications.
Public-company exposure
Large pharmaceutical companies disclose sales of contrast media or diagnostic imaging divisions, not the cost or volume of individual excipients. Meglumine is usually a small input cost relative to the selling price of the finished product. Even when a contrast agent generates substantial revenue, the excipient supplier captures only a small portion of that value.
This creates a critical financial distinction:
- Downstream contrast-media revenue can grow materially.
- Meglumine revenue may grow more slowly because it represents a minor bill-of-materials component.
- Supplier earnings are more sensitive to manufacturing utilization and contract wins than to the retail price of the finished drug.
Which companies participate in the meglumine supply chain?
The supply chain includes three groups:
Contrast-media manufacturers
Major diagnostic-imaging companies include Bayer, Bracco, GE HealthCare, Guerbet and several regional manufacturers. These companies may purchase meglumine directly or source it through API and contract-manufacturing partners.
Pharmaceutical excipient and chemical suppliers
Meglumine is available from pharmaceutical chemical suppliers, excipient distributors and laboratory reagent companies. Supplier names and product grades vary by jurisdiction. A commercial buyer generally evaluates:
- GMP status
- DMF or equivalent regulatory support
- Pharmacopoeial compliance
- Change-control procedures
- Audit history
- Batch-release testing
- Supply redundancy
- Geographic manufacturing footprint
API and contract manufacturers
Many customers do not purchase meglumine as a standalone excipient. They buy a finished meglumine salt, such as a meglumine contrast-agent API, from an API manufacturer. This shifts value capture from the excipient supplier to the API or finished-dose manufacturer.
What regulatory status does meglumine have?
FDA status
The FDA does not approve excipients through the same standalone pathway used for finished drug products. Meglumine gains regulatory acceptance through its use in approved drug products and through supporting documentation submitted by drug sponsors.
The FDA Inactive Ingredient Database is the primary public source for prior use in approved products. Its listings are product- and route-specific, and they should not be treated as blanket authorization for every dosage form or concentration (U.S. Food and Drug Administration, 2024a).
Pharmacopoeial status
Meglumine is covered by major pharmacopoeial systems, including the United States Pharmacopeia and European Pharmacopoeia frameworks. Monograph compliance generally addresses identity, assay, water content, related substances and other quality attributes relevant to pharmaceutical use (United States Pharmacopeial Convention, 2024; European Directorate for the Quality of Medicines & HealthCare, 2024).
European regulatory position
European authorization is product-specific. A meglumine-containing medicine must meet the quality, safety and efficacy requirements applicable to its dosage form and indication. EMA and national regulatory records focus on the finished medicinal product, not on creating a separate marketing authorization for meglumine as an excipient.
What patents protect meglumine-containing products?
The core chemical is mature and is not expected to provide meaningful new composition-of-matter exclusivity. Commercial patent value generally resides in the finished product, formulation, manufacturing process or use.
Formulation patents
Potentially relevant claims may cover:
- Specific meglumine-to-API ratios
- Concentration ranges
- pH ranges
- Osmolality controls
- Stabilizing agents
- Container-closure systems
- Reduced degradation or impurity formation
- Ready-to-use injectable formulations
- High-concentration contrast compositions
Method-of-use patents
Method claims may relate to:
- MRI imaging
- CT imaging
- Angiography
- Organ-specific imaging
- Diagnostic protocols
- Administration sequences
- Patient populations
These patents protect the medicinal product or diagnostic use rather than the excipient itself.
Manufacturing patents
Manufacturing claims may cover:
- Salt formation
- Crystallization
- Purification
- Removal of color bodies and trace metals
- Control of residual solvents
- Particle-size management
- Sterile or low-bioburden processing
For a generic manufacturer, process know-how and regulatory history can be more important than an expired or weak patent estate.
What is the Orange Book status of meglumine?
Meglumine does not have an independent Orange Book listing because the Orange Book lists approved drug products, not standalone excipients. A meglumine-containing drug may appear in the Orange Book if the finished product is an eligible approved prescription drug.
Orange Book analysis must therefore be performed at the product level. Relevant questions include:
- Is the finished drug listed?
- Are patents listed for the drug product?
- Is there regulatory exclusivity?
- Has a generic applicant submitted a Paragraph IV certification?
- Does the listed patent cover the API, formulation, method of use or device?
A generic applicant does not generally challenge "meglumine" as an ingredient. It challenges patents protecting the specific finished product or its use.
Are there Paragraph IV challenges and patent litigation involving meglumine?
Paragraph IV risk is product-specific. Older meglumine-containing contrast agents may face limited patent barriers because many foundational patents have expired. Remaining exposure can involve formulation patents, manufacturing processes, pediatric exclusivity, method-of-use claims or regulatory exclusivity.
There is no commercially meaningful standalone litigation category centered on meglumine as an excipient. The principal litigation risk lies in:
- Generic entry for a branded contrast agent
- API salt or formulation patents
- Injectable composition claims
- Manufacturing-process patents
- Patent settlements between branded and generic manufacturers
Settlement agreements can delay generic entry even when the core chemical is old. The settlement economics depend on the remaining patent term, the product’s revenue, the number of potential entrants and the probability of invalidity or noninfringement.
What generic entry risks exist for meglumine-containing products?
Generic entry risk is high for mature, small-molecule products with expired composition patents and established bioequivalence or pharmaceutical-equivalence pathways.
Risk is lower when the product has:
- Complex injectable manufacturing
- A narrow stability window
- Specialized container systems
- Difficult sterility validation
- Limited API suppliers
- Product-specific clinical or imaging claims
- A remaining formulation patent
- A reference product with limited public manufacturing information
For contrast agents, manufacturing and regulatory execution can delay competition even after core patents expire. A generic entrant must demonstrate consistent quality, impurity control, sterility and performance under the applicable abbreviated approval pathway.
How strong is the patent estate for meglumine?
The patent estate is weak for meglumine as a molecule and potentially moderate for selected finished products.
| Patent layer |
Expected strength |
| Meglumine composition of matter |
Low |
| Basic salt formation |
Low to moderate |
| Specific API-meglumine product |
Product-dependent |
| Injectable formulation |
Moderate in selected cases |
| Manufacturing process |
Moderate where process is difficult to replicate |
| Method of diagnostic use |
Narrow and jurisdiction-dependent |
| Excipient supply know-how |
Commercially relevant but usually not publicly visible |
The strongest barriers are often regulatory and operational rather than patent-based. A validated manufacturing process, qualified supplier network and stable regulatory file can protect market share without creating a durable legal monopoly.
How does meglumine compare with alternative solubilizers and counterions?
Meglumine competes with sodium, potassium, tromethamine, arginine, lysine, ethanolamine, citrate and other salt-forming or pH-adjusting systems.
| Attribute |
Meglumine |
Sodium or potassium salts |
Tromethamine |
Arginine |
| Solubility enhancement |
Often strong |
Compound-specific |
Often strong |
Compound-specific |
| Injectable precedent |
Extensive |
Extensive |
Extensive |
Increasing |
| Regulatory familiarity |
High |
High |
High |
High |
| Osmolality impact |
Product-specific |
Product-specific |
Product-specific |
Product-specific |
| Patent differentiation |
Limited |
Limited |
Limited to moderate |
Moderate in some products |
| Supply complexity |
Low to moderate |
Low |
Moderate |
Moderate |
Selection depends on API chemistry, target pH, osmolality, stability, tolerability and manufacturing practicality. Meglumine is not automatically preferred; it is selected when its physicochemical profile provides a better product outcome than competing counterions.
What is the geographic outlook for meglumine?
Demand is geographically concentrated in regions with significant pharmaceutical manufacturing and diagnostic-imaging capacity.
North America
The United States has strong demand for injectable excipients and contrast media. Regulatory documentation, supplier qualification and drug-shortage resilience are central purchasing criteria.
Europe
European demand benefits from established pharmaceutical manufacturing and pharmacopoeial standards. Buyers often require detailed quality agreements and change-control commitments.
Asia-Pacific
China and India are important manufacturing and sourcing hubs for APIs, excipients and generic injectables. Regional growth can increase volume demand, but local pricing is usually more competitive.
Emerging markets
Latin America, the Middle East and Southeast Asia are expected to remain import-dependent for some contrast media and specialized injectable products. Demand growth depends on imaging infrastructure, public procurement and local registration requirements.
Key Takeaways
- Meglumine is a mature pharmaceutical excipient and counterion with established use in injectable and diagnostic products.
- Its largest commercial demand pool is linked to iodinated and gadolinium-based contrast media.
- Public companies do not generally disclose meglumine-specific revenue, volume or margins.
- Financial growth is likely to be modest, with revenue driven by downstream formulation volume rather than excipient pricing power.
- The core molecule has little meaningful patent protection; product, formulation and manufacturing patents carry most legal value.
- Meglumine has no standalone Orange Book listing. Regulatory and patent analysis must be performed at the finished-product level.
- Generic entry risk is high for mature products with expired composition patents, but complex sterile manufacturing can delay competition.
- Supplier qualification, GMP documentation, pharmacopoeial compliance and supply continuity are major commercial barriers.
- Contrast-media demand supports the market, but meglumine suppliers capture only a small share of downstream product revenue.
- Alternative counterions, including sodium, tromethamine and arginine, limit long-term pricing power.
FAQs
Is meglumine an API or an excipient?
Meglumine can function as either an excipient or an active counterion, depending on the product. In a meglumine salt, it contributes to the drug substance’s chemical form. In other formulations, it acts as a solubilizer or pH modifier.
Is meglumine safe for injectable use?
Meglumine has established injectable use, but safety depends on the finished formulation, dose, route, concentration, impurities and active ingredient. Prior regulatory use does not eliminate the need for product-specific quality and safety assessment.
Does meglumine have a Drug Master File?
A supplier may maintain a DMF or equivalent regulatory package for pharmaceutical-grade meglumine. DMF availability is supplier-specific and does not create an independent market exclusivity right.
Can meglumine be replaced without changing a drug product?
Usually not. Replacing meglumine with another counterion can alter solubility, pH, osmolality, stability, impurity formation, bioavailability and manufacturing conditions. Such a change may require regulatory comparability work or a new product filing.
Does meglumine create a barrier to biosimilar development?
No. Biosimilar regulation applies to biologic products, while meglumine is a small-molecule excipient or counterion. It may affect formulation comparability, but it does not create a biosimilar-specific exclusivity barrier.
References
-
European Directorate for the Quality of Medicines & HealthCare. (2024). European Pharmacopoeia. Council of Europe. https://www.edqm.eu/en/european-pharmacopoeia
-
National Center for Biotechnology Information. (2024). PubChem compound summary for meglumine. PubChem. https://pubchem.ncbi.nlm.nih.gov/
-
United States Pharmacopeial Convention. (2024). Meglumine monograph and United States Pharmacopeia-National Formulary. https://www.usp.org/
-
U.S. Food and Drug Administration. (2024a). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
-
U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files-able-therapeutic-equivalence-evaluations
